Company profile

Bionter AG

Our first in the first family of tailored solutions for the Drug Product sector: the EVE particle counter.The revolutionary analytical testing device, supported with single-use consumables, maintenance and training services, for the biotechs drug product sector is based on a new combination light obscuration technology and smart automation.Different to the existing technologies Bionter's PC100 works non-destructive. i.e. it requires smaller sample volume which can be used for other testing thus reducing costs. Its smart automation workflow drives efficiency and minimizes human interaction and therefore improves reliability, data integrity and in turn patient safety. It also stays compliant to current regulatory requirements offering a low product entrance barrier.

More news about Bionter AG

28.09.2022 09:05

Israeli-Swiss Lean Launchpad Program 2022 supports eight startups

Please login or
register to use the
awards follow feature
21.07.2022 12:00

Ten Biotech startups brace for Boston

Please login or
register to use the
awards follow feature
29.06.2022 12:22

Enerdrape wins the Grand Prize at the 25th >>venture>> edition

Please login or
register to use the
awards follow feature
23.05.2022 14:22

>>venture>> announces 15 winners

Please login or
register to use the
awards follow feature
28.04.2022 08:50

Medtech startup Bionter secures $3 million seed financing

Please login or
register to use the
awards follow feature
Bionter AG

Founded
2020

Kanton
BL


LinkedIn

Homepage

rss